The identification of effective tumor-suppressing neoantigens using a tumor-reactive TIL TCR-pMHC ternary complex
4
조회
0
다운로드
0
인용
0
참고문헌
초록
Neoantigens are ideal targets for cancer immunotherapy because they are expressed de novo in tumor tissue but not in healthy tissue and are therefore recognized as foreign by the immune system. Advances in next-generation sequencing and bioinformatics technologies have enabled the quick identification and prediction of tumor-specific neoantigens; however, only a small fraction of predicted neoantigens are immunogenic. To improve the predictability of immunogenic neoantigens, we developed the in silico neoantigen prediction workflows VACINUSpMHC and VACINUSTCR: VACINUSpMHC incorporates physical binding between peptides and MHCs (pMHCs), and VACINUSTCR integrates T cell reactivity to the pMHC complex through deep learning-based pairing with T cell receptors (TCRs) of putative tumor-reactive CD8 tumor-infiltrating lymphocytes (TILs). We then validated our neoantigen prediction workflows both in vitro and in vivo in patients with hepatocellular carcinoma (HCC) and in a B16F10 mouse melanoma model. The predictive abilities of VACINUSpMHC and VACINUSTCR were confirmed in a validation cohort of 8 patients with HCC. Of a total of 118 neoantigen candidates predicted by VACINUSpMHC, 48 peptides were ultimately selected using VACINUSTCR. In vitro validation revealed that among the 48 predicted neoantigen candidates, 13 peptides were immunogenic. Assessment of the antitumor efficacy of the candidate neoepitopes using a VACINUSTCR in vivo mouse model suggested that vaccination with the predicted neoepitopes induced neoantigen-specific T cell responses and enabled the trafficking of neoantigen-specific CD8 + T cell clones into the tumor tissue, leading to tumor suppression. This study showed that the prediction of immunogenic neoantigens can be improved by integrating a tumor-reactive TIL TCR-pMHC ternary complex.
Abstract
Neoantigens are ideal targets for cancer immunotherapy because they are expressed de novo in tumor tissue but not in healthy tissue and are therefore recognized as foreign by the immune system. Advances in next-generation sequencing and bioinformatics technologies have enabled the quick identification and prediction of tumor-specific neoantigens; however, only a small fraction of predicted neoantigens are immunogenic. To improve the predictability of immunogenic neoantigens, we developed the in silico neoantigen prediction workflows VACINUSpMHC and VACINUSTCR: VACINUSpMHC incorporates physical binding between peptides and MHCs (pMHCs), and VACINUSTCR integrates T cell reactivity to the pMHC complex through deep learning-based pairing with T cell receptors (TCRs) of putative tumor-reactive CD8 tumor-infiltrating lymphocytes (TILs). We then validated our neoantigen prediction workflows both in vitro and in vivo in patients with hepatocellular carcinoma (HCC) and in a B16F10 mouse melanoma model. The predictive abilities of VACINUSpMHC and VACINUSTCR were confirmed in a validation cohort of 8 patients with HCC. Of a total of 118 neoantigen candidates predicted by VACINUSpMHC, 48 peptides were ultimately selected using VACINUSTCR. In vitro validation revealed that among the 48 predicted neoantigen candidates, 13 peptides were immunogenic. Assessment of the antitumor efficacy of the candidate neoepitopes using a VACINUSTCR in vivo mouse model suggested that vaccination with the predicted neoepitopes induced neoantigen-specific T cell responses and enabled the trafficking of neoantigen-specific CD8 + T cell clones into the tumor tissue, leading to tumor suppression. This study showed that the prediction of immunogenic neoantigens can be improved by integrating a tumor-reactive TIL TCR-pMHC ternary complex.
참고문헌 (30)
- Lang, F., "Identification of neoantigens for individualized cancer immunotherapy", Nat. Rev. Drug Discov, 21, pp.261~282 (2022)
- Sahin, U., "Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer", Nature, 547, pp.222~226 (2017)
- Keskin, D. B., "Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial", Nature, 565, pp.234~239 (2019)
- Rojas, L. A., "Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer", Nature, 618, pp.144~150 (2023)
- Ott, P. A., "An immunogenic personal neoantigen vaccine for patients with melanoma", Nature, 547, pp.217~221 (2017)
- Sahin, U., "Personalized vaccines for cancer immunotherapy", Science, 359, pp.1335~1360 (2018)
- Yamamoto, T. N., "Developing neoantigen-targeted T cell-based treatments for solid tumors", Nat. Med, 25, pp.1488~1499 (2019)
- Blass, E., "Advances in the development of personalized neoantigen based therapeutic cancer vaccines", Nat. Rev. Clin. Oncol, 18, pp.215~229 (2021)
- Sette, A., "The relationship between class I binding affinity and immuno genicity of potential cytotoxic T cell epitopes", J. Immunol, 153, pp.5586~5592 (1994)
- Reynisson, B., "NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by con current motif deconvolution and integration of MS MHC eluted ligand data", Nucleic Acids Res, 48, pp.W449~W454 (2020)
- O’Donnell, T. J., "MHCflurry 2.0: Improved pan-allele prediction of MHC Class I-presented peptides by incorporating antigen proces sing", Cell Syst, 11, pp.418~419 (2020)
- Hebeisen, M., "Identifying individual T cell receptors of optimal avidity for tumor antigens", Front. Immunol, 6, pp.582~ (2015)
- Campillo-Davo, D., "The quest for the best : how TCR affinity, avidity, and functional avidity affect TCR-engineered T-cell antitumor responses", Cells, 9, pp.1720~ (2020)
- Schmidt, J., "Prediction of neo-epitope immunogenicity reveals TCR recog nition determinants and provides insight into immunoediting", Cell Rep. Med, 2, pp.100194~ (2021)
- Caushi, J. X., "Transcriptional programs of neoantigen-specific TIL in anti-PD 1-treated lung cancers", Nature, 596, pp.126~132 (2021)
- Oliveira, G., "Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma", Nature, 596, pp.119~125 (2021)
- Lowery, F. J., "Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers", Science, 375, pp.877~884 (2022)
- De Biasi, S., "Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia", Nat. Commun, 11, pp.3434~ (2020)
- Reantragoon, R., "Antigen-loaded MR1 tetramers define T cell receptor het erogeneity in mucosal-associated invariant T cells", J. Exp. Med, 210, pp.2305~2320 (2013)
- Lu, T., "Deep learning-based prediction of the T cell receptor–antigen binding specificity", Nat. Mach. Intell, 3, pp.864~875 (2021)
- Wells, D. K., "Key parameters of tumor epitope immunogenicity revealed through consortium approach improve neoantigen prediction", Cell, 183, pp.818~834 (2020)
- Yost, K. E., "Clonal replacement of tumor-specific T cells following PD-1blockade", Nat. Med, 25, pp.1251~1259 (2019)
- Zheng, L., "Pan-cancer single-cell landscape of tumor-infiltrating T cells", Science, 374, pp.abe6474~ (2021)
- Kreiter, S., "Mutant MHC class II epitopes drive therapeutic immune responses to cancer", Nature, 520, pp.692~696 (2015)
- Fan, J. -B., "Type I interferon regulates a coordinated gene network to enhance cytotoxic T cell-mediated tumor killing", Cancer Discov, 10, pp.382~393 (2020)
- Zhang, L., "Lineage tracking reveals relationships of T cells in colorectal cancer", Nature, 564, pp.268~272 (2018)
- Schmidt, J., "Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors", Nat. Comm, 14, pp.3188~ (2023)
- Lanitis, E., "Mechanisms regulating T-cell infil tration and activity in solid tumors", Ann. Oncol, 28, pp.xii18~xii32 (2017)
- Hilf, N., "Actively personalized vaccination trial for newly diagnosed glio blastoma", Nature, 565, pp.240~245 (2019)
- Wu, C. Y., "Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation", J. Biomed. Sci, 17, pp.88~ (2010)